Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
Share
Why It Matters
Ionis and Roche's new kidney medicine passed an important test. This shows the medicine might actually help sick people, which is good news for the companies.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.